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Biologic response to desmopressin in patients with severe type 1 and type 2
von Willebrand disease: results of a multicenter European study
Augusto B. Federici, Claudine Mazurier, Erik Berntorp, ChristineA. Lee, Inge Scharrer, Jenny Goudemand, Stephan Lethagen,
Ioana Nitu, Gerard Ludwig, Lysiane Hilbert, and Pier M. Mannucci
This study prospectively evaluated the
rate of biologic response to desmopres-
sin (DDAVP) in 66 patients with type 1 or 2
von Willebrand disease (VWD), each of
whom had, on the basis of available
records, a clinically signiﬁcant bleeding
history and at least one of the following
laboratory abnormalities: bleeding time
(BT) longer than 15 minutes, ristocetin
cofactor activity (VWF:RCo) less than 10
IU/dL, factor VIII coagulant activity
(FVIII:C) less than 20 IU/dL (severe VWD).
Beforethestudy,responsivepatientswere
deﬁned as those who, 2 hours after infu-
sion of 0.3 g/kg DDAVP, had increased
baseline values of VWF:RCo and FVIII:C
by at least 3-fold and achieved levels of at
least 30 IU/dL for both and a BT of 12
minutes or less. The rate of biologic re-
sponse varied according to VWD types and
was higher in type 1 (7 of 26, 27%) than in
type 2 (7 of 40, 18%) (type 2A [1 of 15, 7%],
type 2M [3 of 21, 14%], type 2N [3 of 4, 75%]).
Mutations in the VWF gene were previously
known or newly identiﬁed in most patients
with types 2A (n  15 of 15), 2M (n  15 of
21), and 2N (n  4 of 4), but in none of those
with type 1 VWD. Genotype provided more
information than phenotype in predicting
individual responses to DDAVP only in pa-
tientswith2Aand2NVWD.Thisprospective
study showed that the rate of biologic re-
sponse to DDAVP is relatively low not only
in type 2 but also in type 1 VWD when
uniform and stringent criteria for patient
selection and responsiveness are applied.
(Blood. 2004;103:2032-2038)
© 2004 by TheAmerican Society of Hematology
Introduction
There are 2 treatments of choice for von Willebrand disease (VWD):
desmopressin (1-deamino-8-D-arginine vasopressin [DDAVP]) and
transfusion of plasma-derived factor VIII/von Willebrand factor
(FVIII/VWF) concentrates.1 DDAVP is a synthetic analog of
vasopressin that releases and thereby increases 3- to 5-fold the
plasma levels of autologous VWF and FVIII.2,3 Although DDAVP
has been recommended for the treatment of VWD since 1977,4,5 no
prospective studies have been carried out to establish which
patients have well-deﬁned biologic responses to the compound and
whether there is a relationship between response and phenotypic or
genotypic abnormalities of VWF. The goals of this multicenter
prospective study were to determine the rate of a predeﬁned
biologic response to DDAVP in a relatively large number of
patients with types 1 and 2 VWD in Europe, chosen because their
clinical histories were severe enough (severe VWD) to predict the
need for treatment.The study also tried to establish whether there is
a relationship between responsiveness, phenotype, and genotype.
Patients, materials, and methods
Recruitment and inclusion criteria
Patients aged 12 to 65 years—previously classiﬁed as having types 1, 2A,
2M, and 2N VWD according to the currently adopted phenotypic criteria of
theSubcommitteeonVWFoftheScientiﬁcandStandardizationCommittee
(SSC) of the International Society of Thrombosis and Haemostasis
(ISTH)6—were enrolled.The institutional review board approved the study,
and each patient provided informed, written consent.
The total number of patients with types 1 and 2VWD who were followed up
by the 5 hemophilia centers was 912, but only 150 patients met the inclusion
criteria of this study, and only 66 of those gave their informed consent.
Before the study, the participating centers had agreed to deﬁne severe
VWD as a lifelong history of bleeding (including at least 2 episodes severe
enough to require replacement therapy) and at least one of the following
laboratory abnormalities according to the records kept at each center:
bleeding time (BT) longer than 15 minutes, ristocetin cofactor activity
(VWF:RCo) less than 10 IU/dL, and factor VIII coagulant activity
(FVIII:C) less than 20 IU/dL. Eleven patients whose historical data fulﬁlled
the enrollment criteria but who subsequently, at the time of DDAVP
infusion, were found to have a measurement outside these limits remained
in the study based on an intention-to-treat analysis.
Exclusion criteria
Patients with type 3 VWD were excluded because type 3 is known to be
unresponsive to DDAVP, and those with type 2B VWD were excluded
because none of the participating centers used DDAVP to treat type 2B
because of the risk for thrombocytopenia.7 Other exclusion criteria were the
presence of acquired von Willebrand syndrome, antibodies to VWF or
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hyponatremia, seizure, or thrombosis), seropositivity for HIV, pregnancy,
and concomitant epilepsy or cardiovascular diseases.
Identiﬁcation of VWF gene mutations
VWF gene screening not previously carried out by participating centers was
performed at Laboratoire Franc ¸ais du Fractionnement et des Biotechnologies
(C.M., L.H.). The numbering system used for amino acids was in accordance
with the recommendations of the VWF Subcommittee of the ISTH.8
DDAVP administration
Intravenous infusions of 0.3 g/kg body weight DDAVP(diluted in 50-100
mL saline) were given under medical supervision when patients were not
bleeding. Hence, this study does not address the clinical response rate.
Infusions lasted 30 minutes, and venous blood was withdrawn at baseline
and 0.5, 1, 2, and 4 hours after the infusion ended. BT was measured before
and 2 hours after DDAVP using a commercially available device that
delivers 2 standard 1-mm skin horizontal incisions in the volar part of the
forearm (Simplate IIR; BioMe ´rieux, Durham, NC). Aliquots of platelet-
poor plasma samples were obtained and frozen at 70°C until tested in
each laboratory.
Laboratory methods
FVIII:C, VWF antigen (VWF:Ag), and VWF:RCo assays and multimeric
analysis of plasma VWF were performed at each center using locally
standardized methods. Commercial standards calibrated against the World
Health Organization (WHO) standard were used as reference for FVIII:C
and VWF assays. The VWF:RCo/Ag ratio was calculated as a rough index
of VWF functional activity. The lower normal limit of each participating
laboratory ranged between 0.6 and 0.7; therefore, it was agreed before the
study to adopt a lower normal limit of 0.6. This limit is now conﬁrmed in
more than 1200 healthy age- and sex-matched subjects collected as a control
group by another large, ongoing European study on type 1 VWD (unpublished
data). Multimeric analysis was performed by electrophoresis on 1.6%
low–gelling temperature agarose gel in patients with type 2AVWD.9
Criteria for biologic response to DDAVP
Before the study was started, responsive patients were deﬁned as those who,
2 hours after the end of DDAVP infusion, had increases of plasma FVIII:C
and VWF:RCo of at least 3-fold over baseline and reached levels for
both values of at least 30 IU/dL and a BT of 12 minutes or less (12 min-
utes was the upper BT limit agreed to by all participating centers using the
same device).
Statistical analysis
Laboratory data were expressed as means  SD. The t test was used to
compare results of types 2A, 2M, and 2N with those of all type 1 VWD.
P values less than .05 were considered statistically signiﬁcant.
Results
Overall results in patients with types 1 and 2 VWD
Twenty-six type 1 and 40 type 2 patients met the inclusion criteria;
none had to be excluded because of severe adverse effects on
previous exposures to DDAVP. Table 1 shows the mean laboratory
values (mean  SD) before and 2 hours after DDAVP and the
relationshipbetweenDDAVPresponse,phenotypes,andgenotypes.
Criteria for responsiveness to DDAVP were met by 7 of 26
(27%) of type 1 patients and 7 of 40 (18%) of type 2 patients (all
subtypes). Details on the changes of the plasma levels of FVIII/
VWF measurements and BT after DDAVP, according to VWD
Table 1. DDAVP response by bleeding time and FVIII/VWF activities before and 2 hours after infusion, in patients with different types
of von Willebrand disease divided by phenotypes and gene mutations
VWD types
No. responsive
patients of total
FVIII:C, U/dL VWF:RCo, U/dL Bleeding time, min VWF:RCo/Ag ratio FVIII:C/VWFAg ratio
Before After 2 h Before After 2 h Before After 2 h Before After 2 h Before After 2 h
All type 1 7o f2 6 3 9 24 130  64 19  20 59  58 24  10 11  6 0.8  0.4 0.9  0.3 2.3  0.3 2.3  0.2
VWF:RCo/Ag greater than 0.6 6 of 18 44  28 138  72 24  22 77  62 23  91 1  7 0.9  0.2 1.0  0.3 2.7  0.3 2.6  0.2
VWF:RCo/Ag less than 0.6 1 of 8 28  5* 110  38 7  1* 19  10* 18  12 9  5 0.5  0.3* 0.7  0.2 1.9  0.2 1.7  0.2
All type 2A 1o f1 5 4 0 14 135  56 11  9* 29  20* 28  52 3  7* 0.3  0.2* 0.2  0.1* 1.4  0.8* 1.4  0.7*
G550R 0 of 1 35 277* 6* 6* 30* 30* 0.1* 0.1* 0.6* 3.2
C1272G 0 of 1 33 110 6* 16* 30* 30* 0.3* 0.2* 1.6* 1.3*
S1506L 0 of 5 36  12 91  18* 12  13 19  9* 30* 26  8* 0.4  0.2* 0.3  0.2* 1.7  0.8* 1.0  0.2*
R1597W 1 of 3 45  5 144  91 0  23 9  9* 24  11 18  10* 0.3  0.1* 0.3  0.1* 1.4  0.2* 1.3  0.1*
I1628T 0 of 3 45  8 149  91 7  53 8  12* 27  41 7  6* 0.4  0.2* 0.3  0.2* 0.9  0.3* 1.1  0.2*
G1629R 0 of 1 61 203* 30 60 30* 20* 0.3* 0.3* 0.6* 0-9*
V1665E 0 of 1 27 102* 6* 10* 30* 30* 0.2* 0.1* 1.2* 1.0*
All type 2M 3o f2 1 3 7 15 113  41* 12  63 9  14* 17  71 2  6 0.5  0.2* 0.7  0.3 2.1  1.2 1.9  0.9
Vicenza, R1205H 0 of 1 4* 21* 6* 18* 13 7 0.5* 0.6* 0.3* 0.7*
R1315C 0 of 3 39  99 2  11* 7  2* 25  3* 20  01 2  6 0.3  0.1* 0.6  0.2 2.0  0.7 2.1  0.5
R1374C 1 of 9 34  3 117  24 16  11 42  16 21  51 5  7 0.5  0.3* 0.5  0.3 1.9  0.8 2.1  0.3
R1374H 1 of 2 31-44 100-132 13-38 12-39 16-15 11-10 0.6-0.5 0.4-0.5 1.3-1.6 0.9*-1.8
undeﬁned 1 of 6 45  12 133  18 10  54 4  61 2  4* 9  3 0.5  0.3* 0.6  0.2 2.5  1.2 1.9  0.7
Type 2N 3o f4 1 6 7* 106  60* 40  13* 153  72* 7  3* 6  2* 0.7  0.1 0.9  0.1 0.3  0.2* 0.6  0.3*
R854Q  R854Q 1 of 1 24 165 52* 202* 5* 5* 0.7 1.0 0.4* 0.9*
R854Q  null 1 of 1 13* 115 26 98* 11* 8 0.8 0.8 0.3* 0.8*
R854Q  C1060R 1 of 1 18* 121 48* 227* 6* 6* 0.7 0.8 0.2* 0.6*
C1060R  null 0 of 1 7* 23* 29 85* 5* 4* 0.7 0.8 0.1* 0.2*
Numbers indicate mean  SD or individual values for single patients.
To calculate the mean values of VWF:RCo and the VWF:RCo/Ag ratios, VWF:RCo levels below the limit of sensitivity of the assay (6 IU/dL) were taken to 6 IU/dL.
To calculate mean and SD for bleeding times, values 30 min were taken to 30 min.
*P  .05 compared with all patients with type 1 VWD.
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Responses in patients with type 1 VWD
The VWF gene mutations in patients with type 1 VWD were not
identiﬁed previously or as part of this study. Figure 1 shows that
after DDAVP administration, FVIII:C and VWF:RCo levels in-
creased in most patients, with mean relative increases of 3.6- and
3.7-fold, respectively. However, only 7 of 26 (27%) patients met
the criterion of responsiveness because the threshold levels of both
measurements were not attained in the remaining 19 patients. BT,
prolonged on baseline, was signiﬁcantly shortened after 2 hours in
patients with type 1 VWD and became shorter or normal (less than
12 minutes) in most patients.
The VWF:RCo/Ag ratio was the measurement retrospectively
found to better separate responders from nonresponders. Table 1
shows that among 18 patients who had normalVWF:RCo/Ag ratios
(greater than 0.6) before and 2 hours after DDAVP, 6 were
responsive; among the remaining 8 patients who had VWF:
RCo/Ag ratios below 0.6, only one was responsive, even though
the mean relative increases of VWF:RCo were similar in the 2
subgroups. Mean FVIII:C/VWF:Ag ratios were similar (2.3) before
and 2 hours after DDAVP(Table 1).
Responses in patients with type 2A VWD
Only 1 of 15 (7%) patients with type 2AVWD met the criteria for
responsiveness. Figure 2 shows that though all 15 patients had normal
FVIII:C levels (more than 50 U/dL) 2 hours after DDAVP administra-
tion, VWF:RCo reached the threshold levels of 30 U/dL in 5 patients
only. The BT was initially prolonged in most patients and improved or
became normal in only 3 patients (Figure 2). Mean FVIII:C/
VWF:Ag ratios were similar (1.4) before and 2 hours after DDAVP
but were lower than in patients with type 1 VWD (Table 1).
Gene mutations were G550R (1 patient), C1272G (1 patient),
S1506L (5 patients), R1597W (3 patients), I1628T (3 patients),
G1629R (1 patient), and V1665E (1 patient). In detail, Table 1
shows that the patient with the G550R mutation had a large
relative increase in FVIII:C but no change in VWF:RCo or BT.
The only patient with the C1272G mutation had increases of
both FVIII:C and VWF:RCo, but the BT remained prolonged
(Table 1).
All 13 patients with mutations S1506L, R1597W, I1628T,
G1629R, V1665E had markedly increased FVIII:C (Table 1) but
were ultimately classiﬁed as unresponsive, with the exception of
1 of the 3 patients with R1597W.
The multimeric pattern of VWF before and after DDAVPwas
evaluated in 4 patients with mutations most frequently associ-
ated with type 2A VWD and correlated with changes in
VWF:RCo, VWF:Ag, VWF:RCo/Ag, and BT (Table 2). In
patients with mutations S1506L10 and V1665E,11 causing defec-
tive intracellular transport and assembly of VWF (so-called
group 1 defects), there were few improvements after DDAVP in
the defective multimeric structure (Figure 3), persistence of a
prolonged BT, and little increase in VWF:RCo (Table 2). In
contrast, in patients with mutations R1597W10 and G1629R12
that resulted in VWF multimers more sensitive to proteolysis
after secretion in plasma (group 2 defects), there was a transient
increase of large multimers (Figure 3) associated with a
transient normalization of BTand an improvement ofVWF:RCo
values (Table 2).
Figure 1. Biologic responses to DDAVP in 26 patients
with type 1 VWD. Changes of FVIII:C (U/dL) and
VWF:RCo (U/dL) are shown for each patient before and
30minutes,2hours,and4hoursafterDDAVPadministra-
tion. BT results expressed in minutes are reported only
before and 2 hours after DDAVP. Limits of FVIII:C,
VWF:RCo,andBTusedinthisstudytodeﬁneresponsive-
ness (see “Criteria for biologic response to DDAVP”) are
shown by the zone indicated in gray. Patients responsive
(F) and unresponsive (E) to DDAVP.
Figure 2. Biologic responses to DDAVP in 15 patients
with type 2A VWD. Changes of FVIII:C (U/dL) and
VWF:RCo (U/dL) are shown for each patient before and
30minutes,2hours,and4hoursafterDDAVPadministra-
tion. BT results expressed in minutes are reported only
before and 2 hours after DDAVP. Limits of FVIII:C,
VWF:RCo,andBTusedinthisstudytodeﬁneresponsive-
ness (see criteria for DDAVP response) are shown by the
zone indicated in gray. Patients responsive (F) and
unresponsive (E) to DDAVP.
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Only 3 of 21 (14%) patients with type 2MVWD met the criteria for
responsiveness. Figure 4 shows that all but one patient reached the
threshold FVIII:C levels of at least 30 U/dL 2 hours after DDAVP
administration, whereas VWF:RCo became higher than 30 U/dLin
only 14 patients. The prolonged BT was normal at 2 hours in 13 of
21 (62%) patients. Table 1 shows that in the group as a whole, the
relative increase at 2 hours for FVIII:C was similar to that of
VWF:RCo, with modest improvements in the mean values of
VWF:RCo/Ag ratios and BT.
Gene mutations were known in 15 of 21 (70%) patients:
R1205H (1 patient), R1315C (3 patients), R1374C (9 patients), and
R1374H (2 patients). The patient heterozygous for the R1205H
mutation, Vicenza-type VWD,13 had the following baseline pheno-
type: VWF:RCo less than 6 U/dL; VWF:Ag, 13 U/dL; FVIII:C,
4 U/dL; and VWF:RCo/Ag ratio, 0.5. Despite the relative 5-fold
increase in FVIII:C and the 3-fold increase inVWF:RCo, levels for
FVIII:C and VWF:RCo did not reach at least 30 U/dL; therefore,
the patient was classiﬁed as unresponsive. None of the 3 patients
with the R1315 mutation was responsive (Table 1). In 8 of 9
patients from Sweden with the R1374C mutation, there was a
consistent lack of response to DDAVP (Table 1). The responses of
FVIII:C andVWF:RCo in the 2 patients with the R1374H mutation
were similar to those found in patients with R1374C (Table 1); only
1 of these patients was responsive. Five of 6 patients with unknown
mutations (2M “undeﬁned”) were classiﬁed as unresponsive,
despite increases of VWF:RCo and FVIII:C levels (Table 1).
Responses in patients with type 2N VWD
Figure 5 and Table 1 show that in 4 patients with type 2N VWD,
FVIII:C was low andVWF:RCo,VWF:RCo/Ag ratio, and BTwere
normal in all patients at baseline. The 3 patients with the R854Q
mutation on one allele were responsive to DDAVP. The fourth
patient, with the C1060R mutation, was unresponsive because FVIII:C
levels of only 23 U/dLwere reached after DDAVPinfusion (Table 1). In
the 3 patients heterozygous for R854Q, there was a 6.7- to 8.8-fold
increase in FVIII:C, and the FVIII:C/VWF:Ag ratios were signiﬁ-
cantly lower (0.3  0.2) than in patients with types 1, 2A, and 2M
and remained lower (0.6  0.3) at 2 hours after DDAVP (Table 1).
Discussion
Although DDAVPhas been used for 25 years in the management of
VWD, there has been no prospective study in well-characterized
patients, with objective criteria to assess biologic or clinical
Figure 3. VWF multimeric structure before and after DDAVP administration in 4
patients with type 2A VWD. Plasma of healthy controls (NP) and of 4 patients with
type 2A VWD with mutations S506L (A), R1597W (B), G1629R (C), and V1665E (D)
before and 30 minutes, 1 hour, 2 hours, and 4 hours after DDAVP administration are
shown (from left to right). In the 2 patients with the ﬁrst group of type 2A defects
(S1506LandV1665E),therewerenochangesintheproportionofthehigh-molecular–
weight multimers after DDAVPor in the prolonged BT(more than 30 minutes) and low
VWF:RCo/Ag ratios (less than 0.30) observed at baseline (Table 2). Conversely, in
the 2 patients with the second group of type 2A defects (R1597W and G1629R), a
transient appearance of high-molecular–weight multimers is observed after DDAVP
administration and transient normalization (6 and 10 minutes) of the prolonged BT
(more than 30 minutes at baseline). The low VWF:RCo/Ag ratios (less than 0.30)
observed at baseline did not change appreciably (Table 2).
Table 2. VWF measurements and BT before and after DDAVP in selected patients with type 2A VWD
Time after DDAVP, h VWF:RCo, U/dL VWF:Ag, U/dL VWF:RCo/Ag ratio Bleeding time, min
Normal values (range) 110  35 (46-202) 112  36 (50-218) 0.99  0.23 (0.63-1.75) 5  2 (3-7)
Patient with S1506L, group 1 Baseline 6 22 0.27 30
0.5 14 44 0.32 30
1 22 68 0.32 30
2 24 77 0.29 30
4 14 64 0.22 30
Patient with R1597W, group 2 Baseline 6 31 0.19 30
0.5 65 100 0.65 NT
1 60 134 0.45 6.30
2 53 112 0.47 12
4 36 96 0.37 15
Patient with G1629R, group 2 Baseline 30 100 0.30 30
0.5 67 190 0.35 NT
1 79 236 0.33 10
2 60 232 0.26 20
4 62 252 0.25 30
Patient with V1665E, group 1 Baseline 6 22 0.27 30
1 10 91 0.11 30
2 13 95 0.14 30
4 10 104 0.10 30
See also Figure 3 for these data.
NT indicates not tested.
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evaluated using changes in measurements of FVIII:C, VWF:RCo,
and BT, which are commonly used as surrogate markers of clinical
efﬁcacy. The patient population included 66 patients with type 1 or
2 VWD who were classiﬁed according to preestablished uniform
criteria and whose disease was clinically severe enough in the past
to require treatment to control bleeding. Inclusion criteria excluded
a sizable group of patients with mild and moderately severe VWD,
identifying a clinically homogeneous patient population. At the
time of infusion no patient was bleeding, so the clinical response
rate could not be evaluated. Overall, only approximately one ﬁfth
of the patients had a biologic response to DDAVP, deﬁned as the
concomitant attainment of at least a 3-fold increase of FVIII:C and
VWF:RCo to levels of at least 30 IU/dL and a BT shorter than 12
minutes. These arbitrary criteria for biologic response were the
consensus target levels of useful clinical responses based on the
experiences of the participating centers.
The rate of biologic response varied in different VWD types.As
expected, patients with type 1 VWD responded (27%) better than
patients with type 2 taken as a whole (18%), but they responded
less frequently than claimed in previous studies.14 The FVIII/VWF
ratios of type 1 VWD patients were much higher than those of type
2A VWD patients, as recently reported.15 The values of the ratio
between VWF:RCo and VWF:Ag levels, before and 2 hours after
DDAVP, provided some understanding of the varied responses.
According to the current deﬁnition, in type 1 VWD the VWF
protein (VWF:Ag) and its functional activity (VWF:RCo) should
be similarly low, giving a ratio close to 1, as in healthy persons.
However, there were 8 type 1 patients who had ratios below the
lower normal limit (0.6), both at baseline and after DDAVP, among
whom 6 were unresponsive to DDAVP. According to the current
classiﬁcation criteria, these patients are genuine type 1 because the
“distribution of VWF multimers is normal or nearly normal.”16
On the other hand, there is the distinct possibility that these
patients with lowVWF:RCo/Ag ratio, decreased ristocetin-induced
platelet agglutination, and normal or near normal multimeric
structure are carriers of a qualitatively abnormalVWF protein in its
interaction with platelets and that they should be classiﬁed as
having type 2M VWD, as recently suggested.17-19 This hypothesis
can be only validated by the knowledge of gene defects and by the
demonstration that the expressed recombinant proteins have abnor-
mal reactions with platelet membrane glycoproteins. In the absence
of these molecular data, the 8 patients with low VWF:RCo/Ag
ratios were still kept in the type 1 VWD group, as originally
indicated by the participating centers at the time of enrollment.
Only 1 of 17 patients with type 2AVWD responded to DDAVP,
because even though FVIII:C levels usually increased and the
relative increase of VWF:RCo was on average 3-fold above
baseline in most patients, the target levels of 30 U/dL were not
reached. It has been reported that some patients with type 2AVWD
respond better than others to DDAVP.20,21 However, these reports
predated knowledge of gene defects and the description of different
mechanisms of type 2A VWD (intracellular processing defects vs
increased extracellular proteolysis).10-12 In this study the changes of
FVIII/VWF activities, including the multimeric pattern, were
documented using 4 patient examples, 2 with the features of group
1 (S1506L and V1665E) and 2 with the features of group 2
(R1597W and G1629R), as established by expression studies.10-12
According to our criteria, all patients with type 2A disease were
unresponsive to DDAVPwhatever the mutation and the mechanism
of VWF dysfunction. However, patients with group 2 mutations
behaved differently than did those with group 1 defects, with
Figure 4. Biologic responses to DDAVP in 21 patients
with type 2M VWD. Changes of FVIII:C (U/dL) and
VWF:RCo (U/dL) are shown for each patient before and
30minutes,2hours,and4hoursafterDDAVPadministra-
tion. BT results expressed in minutes are reported only
before and 2 hours after DDAVP. Limits of FVIII:C,
VWF:RCo,andBTusedinthisstudytodeﬁneresponsive-
ness (see criteria for DDAVP response) are shown by the
zone indicated in gray. Patients responsive (F) and
unresponsive (E) to DDAVP.
Figure 5. Biologic responses to DDAVP in 4 patients
with type 2N VWD. Changes of FVIII:C (U/dL) and
VWF:RCo (U/dL) are shown for each patient before and
30minutes,2hours,and4hoursafterDDAVPadministra-
tion. BT results expressed in minutes are reported only
before and 2 hours after DDAVP. Limits of FVIII:C,
VWF:RCo,andBTusedinthisstudytodeﬁneresponsive-
ness (see criteria for DDAVP response) are shown by the
zone indicated in gray. Patients responsive (F) and
unresponsive (E) to DDAVP.
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understood whether these observations are associated with a better
clinical response.
Most patients with type 2M VWD were poorly responsive to
DDAVP. These patients have a full set of multimers, but VWF
functions abnormally in the interaction with platelets. This is
shown either by ﬁnding a low VWF:RCo/Ag ratio in plasma or by
demonstrating an abnormal function of the expressed recombinant
protein when the mutation is known. In a relatively large group of
Swedish patients from different kindreds carrying the same muta-
tion (R1374C), the response to DDAVP was consistently poor.
Previous expression studies carried out in these patients have
shown that mutant VWF reacts abnormally with platelets.19,22 A
transient correction of the VWF:RCo/Ag ratios that correlates with
a shortening of the BT can be observed in patients with type 2M
VWD (data not shown in detail), as recently reported.23
Patients with Vicenza VWD are characterized by the presence
in plasma of an abnormal set of ultralarge multimers, concomi-
tantly low levels of VWF and FVIII:C, and mildly prolonged BT.
They are currently classiﬁed as having type 2M VWD because
multimers are present and VWF is thought to be dysfunctional.13
Only one patient with type 2M Vicenza, carrying the R1205H
mutation, was investigated. The patient was unresponsive to
DDAVP, with FVIII:C and VWF:RCo levels below 30 IU/dL
2 hours after DDAVP even though the BT was markedly shortened
from 13 to 7 minutes. BTwas normalized despite the relatively low
levels of VWF because the “supranormal” multimers are highly
effective in platelet adhesion. FVIII/VWF activities were measured
for only 4 hours after DDAVP, so the clearances from plasma could
not be determined. Therefore, it is difﬁcult to compare this patient
with the recent report of a group of Vicenza patients who exhibited
accelerated clearance of FVIII/VWF measurements.23,24 The latter
feature does not seem to be speciﬁc for Vicenza VWD because
other types of VWD have been shown to have a short VWF
half-life.25,26
Three of 4 patients of the small group with type 2NVWD, all of
whom carried the mutation R854Q, associated with some residual
binding of FVIII:C to the abnormal VWF and characterized by low
FVIII:C levels and normal VWF levels responded to DDAVP with
large increases of FVIII:C.27 On the other hand, the fourth patient,
carrying both a null mutation and the C1060R mutation associated
with a complete absence of FVIII binding, was unresponsive.
Therefore, at least in this group of patients, a relationship appears
to exist between the type of gene mutation, the related functional
abnormalities, and the response to DDAVP.
From this prospective study designed to understand DDAVP
responsiveness through the knowledge of phenotypes and geno-
types, we conclude that when preestablished uniform criteria are
applied, the rate of biologic response in severe types 1 and 2 VWD
is lower than previously described. Genotypic data were more
useful than knowledge of phenotype only for patients with types
2Aand 2N VWD.
Note added in proof. After this manuscript was accepted for
publication,Canadianinvestigatorspublishedastudyonresponsive-
ness to desmopressin in 75 patients with type 1 or type 2A von
Willebrand disease.28 (S. Revel-Vilk et al, J Pediatr Hematol Oncol
2003;25:874-879).
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